| Antigenic fragment of human t-lymphotropic virus -> Monitor Keywords |
|
|
 
Antigenic fragment of human t-lymphotropic virusRelated Patent Categories: Chemistry: Molecular Biology And Microbiology, Micro-organism, Tissue Cell Culture Or Enzyme Using Process To Synthesize A Desired Chemical Compound Or Composition, Preparing Compound Containing Saccharide Radical, N-glycoside, , Nucleotide, Polynucleotide (e.g., Nucleic Acid, Oligonucleotide, Etc.)Antigenic fragment of human t-lymphotropic virus description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20060127989, Antigenic fragment of human t-lymphotropic virus. Brief Patent Description - Full Patent Description - Patent Application Claims
RELATED APPLICATIONS [0001] This application is a continuation application and claims priority to U.S. application Ser. No. 10/423,156, filed Apr. 25, 2003 (now allowed), and Taiwan Application Serial No. 91135980, filed Dec. 12, 2002, the contents of which are incorporated herein in their entirety. SUMMARY OF THE INVENTION [0002] It is therefore a primary object of the present invention to provide fusion proteins of human T-lmphotropic virus (HTLV) with Glutathione S-transferase (GST) or Thioredoxin. The fusion proteins have the advantage of high specific and sensitive to is HTLV-I/II and the preparation of these proteins is safe and effective. In addition, the fusion proteins can be applied in HTLV-I/II assay. Using genomic engineering, the antigenic viral recombinant protein expressed by E. coli can be prepared in large quantities at low cost. Moreover, avoiding the cultivation and purification of HTLV, the preparation of the present invention is safer than the current preparation. [0003] Accordingly, in a first aspect, the invention features an isolated peptide comprising an antigenic fragment of HTLV-I gp21 having the amino acid sequence of SEQ ID No: 3. [0004] The invention also features an isolated peptide comprising an antigenic fragment of HTLV-II gp21 having the amino acid sequence of SEQ ID No: 4. [0005] In addition, the present invention features an isolated nucleic acid encoding an antigenic fragment of HTLV-I gp21, wherein the nucleic acid comprises the nucleotide sequence of SEQ ID No: 55. [0006] The present invention also features an isolated nucleic acid encoding an antigenic fragment of HTLV-II gp21, wherein the nucleic acid comprises the nucleotide sequence of SEQ ID No: 56. [0007] Both of the aforementioned nucleic acids encoding antigenic fragments in the invention can be optionally combined with glutathione S-transferase (GST) or thioredoxin (thio) to form 4 recombinant nucleic acids as below. [0008] 1. A nucleic acid encoding GST/HTLV-I gp21 fusion protein, wherein the nucleic acid comprises the nucleotide sequence of SEQ ID No: 57. [0009] 2. A nucleic acid encoding Thio/HTLV-I gp21 fusion protein, wherein the nucleic acid comprises the nucleotide sequence of SEQ ID No: 59. [0010] 3. A nucleic acid encoding GST/HTLV-II gp21 fusion protein, wherein the nucleic acid comprises the nucleotide sequence of SEQ ID No: 58. [0011] 4. A nucleic acid encoding Thio/HTLV-II gp21 fusion protein, wherein the nucleic acid comprises the nucleotide sequence of SEQ ID No: 60. [0012] In addition, the present invention also features an expression vector comprising a nucleic acid encoding any of the four fusion proteins operably linked to a nucleotide sequence regulatory element that controls expression of the nucleic acid and a process for producing the HTLV antigenic fragments. The process comprises introducing an expression vector comprising a nucleic acid encoding any of the four fusion proteins into a cell, culturing the cell under conditions suitable for production of the fusion protein, and recovering the fusion protein from the cell culture. [0013] In one embodiment of the process, the cell is Escherichia coli, for example, BL21(DE3) strain. For the production of GST/HTLV gp21 fusion protein, recovery is enabled by glutathione sepharose column; for the production of Thio/HTLV gp21 fusion protein, recovery is enabled by NiNTA column. [0014] Accordingly, the four nucleic acids encode four fusion proteins as below. [0015] 1. GST/HTLV-I gp21 fusion protein comprising the amino acid sequence of SEQ ID No: 5. [0016] 2. Thio/HTLV-I gp21 fusion protein comprising the amino acid sequence of SEQ ID No: 7. [0017] 3. GST/HTLV-II gp21 fusion protein comprising the 10 amino acid sequence of SEQ ID No: 6. [0018] 4. Thio/HTLV-II gp21 fusion protein comprising the amino acid sequence of SEQ ID No: 8. [0019] Another aspect of the invention features a kit for the detection of human T-lymphotrophic virus(HTLV). The kit comprises a solid substrate, a first HTLV gp21 antigenic fragment immobilized on the solid substrate, a blocking solution for blocking a HTLV gp21 antigenic fragment-unbound region on the solid substrate, a second HTLV gp21 antigenic fragment, a wash solution, and a signal-producing means operably linked to the second HTLV gp21 antigenic fragment to produce a signal, wherein the first and second HTLV gp21 are selected from any of the fusion proteins. [0020] In one embodiment of the kit in the invention, the first HTLV gp21 is Thio/HTLV-II gp21 fusion protein, and the second HTLV gp21 is GST/HTLV-I gp21 fusion protein. BRIEF DESCRIPTION OF THE DRAWINGS [0021] The present invention will be more fully understood and further advantages will become apparent when reference is made to the following description of the invention and the accompanying drawings in which: Continue reading about Antigenic fragment of human t-lymphotropic virus... Full patent description for Antigenic fragment of human t-lymphotropic virus Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Antigenic fragment of human t-lymphotropic virus patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Antigenic fragment of human t-lymphotropic virus or other areas of interest. ### Previous Patent Application: Microorganism producing hyaluronic acid and purification method of hyaluronic acid Next Patent Application: Synthetic nucleic acid molecule compositions and methods of preparation Industry Class: Chemistry: molecular biology and microbiology ### FreshPatents.com Support Thank you for viewing the Antigenic fragment of human t-lymphotropic virus patent info. IP-related news and info Results in 0.19162 seconds Other interesting Feshpatents.com categories: Computers: Graphics , I/O , Processors , Dyn. Storage , Static Storage , Printers 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
